NCT07355387 Home Based Functional Balance Intervention for Multiple Sclerosis
| NCT ID | NCT07355387 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Illinois at Chicago |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-11-24 |
| Primary Completion | 2026-11-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2025-11-24 with a primary completion date of 2026-11-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of daily living among persons with multiple sclerosis (PwMS). Combined Specific Aims: Aim 1: Examine the effect of the FBI (Intervention Group) on physical function in PwMS compared to a stretching program (Control Group). Hypothesis 1: After four months of training, the FBI group will show significantly greater improvements in physical function compared to the stretching group. Aim 2: Examine the effect of the multicomponent FBI on cognitive function in PwMS compared to the stretching program. Hypothesis 2: After four months of training, the FBI group will show significantly greater improvements in cognitive function compared to the stretching group. Aim 3: Examine the effects of the multicomponent FBI compared to the Control Group among PwMS on measures of daily living (dual-task performance, balance confidence, community mobility, and quality of life). Hypothesis 3: After four months of training, the FBI group will show significantly greater improvements in measures of daily living compared to the stretching group. All assessment sessions will be conducted virtually via Zoom. All measures collected during the initial screening, pre-training assessment, training progression, and mid- and post-training assessment sessions will be administered either via Zoom with a Helper Buddy present or through survey links sent to participants via the UIC REDCap system. The training sessions will be performed independently by the participants in the presence of a Helper Buddy. The investigators will recruit 75 people with multiple sclerosis (PwMS) for this study. Eligible participants will be randomized to either the FBI (Intervention) or stretching (Control) group, followed by an onboarding session with a designated Helper Buddy. Training will occur twice weekly for four months. Based on the anticipated attrition rate, the investigators aim for 40 PwMS to complete the post-training assessments and finish the study.
Eligibility Criteria
Inclusion Criteria Telephone Screening Inclusion Criteria: 1. Age 40-90 years. 2. Self-reported diagnosis of Multiple Sclerosis. 3. On stable disease-modifying therapy for ≥6 months. 4. No PT/OT balance-related therapy in the past 6 months. 5. Able to stand from a chair independently (with or without hand support). 6. Score 25-75% on the 12-item MS Walking Scale. 7. No other neurological, cardiopulmonary, musculoskeletal, or systemic conditions affecting standing/walking. 8. English speaking. 9. Willing to complete all study procedures including Zoom sessions. 10. Has reliable internet access. 11. Has a helper buddy available for all sessions. 12. Possible mild cognitive impairment based on self-report. Initial Screening Inclusion Criteria: 1. Moderate disability: ePR-EDSS score 4.0-6.5. 2. Mild cognitive impairment: MoCA 18-25, or Jak/Bondi criteria for those scoring 26-30. 3. Physically inactive or moderately active (Godin score \<24). 4. Cardiovascular safety parameters within acceptable limits. 5. No global aphasia (Mississippi Aphasia Screening Test ≥71 percent). 6. Berg Balance Scale score ≥40/56. 7. Able to walk 1 block with or without an assistive device. Helper Buddy Inclusion Criteria: 1. Age ≥18 years. 2. Lives within close proximity to the participant. 3. No self-reported major medical conditions limiting safety assistance. 4. English speaking. 5. Able to attend all training and assessment sessions. 6. Able to assist with basic safety, positioning, and communication with the research team. 7. Has internet access and can use Zoom. Exclusion Criteria Telephone Screening Exclusion Criteria: 1. MS relapse or exacerbation within the past 3 months. 2. Recent major surgery (\<6 months) or hospitalization (\<3 months). 3. Resting shortness of breath or uncontrolled pain \>3/10. 4. Uncontrolled hypertension or diabetes. 5. Bone fracture in the past 6 months. 6. Disability limiting activities of daily living. 7. History of epilepsy or uncontrolled seizures in past year. 8. Sedative medication use that may interfere with training. 9. Use of Alzheimer's/dementia-modifying drugs or enrollment in AD clinical trials. 10. Use of antidepressants or anxiety medications. 11. Moderate or high risk on PAR-Q (≤1 "yes" response). 12. Severe cognitive impairment (TICS-M ≥18). 13. Currently receiving cognitive or physical rehabilitation. 14. Pacemaker use. Initial Screening Exclusion Criteria: 1. Cardiovascular parameters outside safety limits (HR, BP, O₂ saturation). 2. Global aphasia (Mississippi \<71 percent). 3. Peripheral nerve injury. 4. Berg Balance Scale \<40/56. 5. Inability to walk one block with or without an assistive device. Population Exclusions: 1. Non-English speakers (protocol delivered only in English). 2. Individuals under 18 years. 3. Pregnant individuals. 4. Prisoners or other vulnerable populations.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07355387 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 90 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07355387 currently recruiting?
Yes, NCT07355387 is actively recruiting participants. Contact the research team at tbhhat6@uic.edu for enrollment information.
Where is the NCT07355387 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07355387 clinical trial?
NCT07355387 is sponsored by University of Illinois at Chicago. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.